AMGXF Quote, Financials, Valuation and Earnings

PeptiDream has a net margin of -737.34% compared to AnGes's net margin of -24.41%. AnGes's return on equity of -33.92% beat PeptiDream's return on equity of 34.1%.

AnGes has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that AnGes has higher upside potential than PeptiDream, analysts believe AnGes is more attractive than PeptiDream.

AnGes has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.542, suggesting its less volatile than the S&P 500 by 45.756%.

AnGes has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnGes pays -- of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.

AnGes quarterly revenues are $1.1M, which are smaller than PeptiDream quarterly revenues of $27.8M. AnGes's net income of -$8.2M is lower than PeptiDream's net income of -$6.8M. Notably, AnGes's price-to-earnings ratio is -- while PeptiDream's PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnGes is 22.97x versus 5.17x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

SanBio has a net margin of -737.34% compared to AnGes's net margin of --. AnGes's return on equity of -33.92% beat SanBio's return on equity of --.

AnGes has a consensus price target of --, signalling downside risk potential of --. On the other hand SanBio has an analysts' consensus of -- which suggests that it could fall by --. Given that AnGes has higher upside potential than SanBio, analysts believe AnGes is more attractive than SanBio.

AnGes has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison SanBio has a beta of -0.584, suggesting its less volatile than the S&P 500 by 158.36%.

AnGes has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SanBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnGes pays -- of its earnings as a dividend. SanBio pays out -- of its earnings as a dividend.

AnGes quarterly revenues are $1.1M, which are larger than SanBio quarterly revenues of --. AnGes's net income of -$8.2M is lower than SanBio's net income of -$5.8M. Notably, AnGes's price-to-earnings ratio is -- while SanBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnGes is 22.97x versus 113.78x for SanBio. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of -737.34% compared to AnGes's net margin of -11.44%. AnGes's return on equity of -33.92% beat Nxera Pharma's return on equity of -8.65%.

AnGes has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that AnGes has higher upside potential than Nxera Pharma, analysts believe AnGes is more attractive than Nxera Pharma.

AnGes has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.360, suggesting its less volatile than the S&P 500 by 64.028%.

AnGes has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnGes pays -- of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend.

AnGes quarterly revenues are $1.1M, which are smaller than Nxera Pharma quarterly revenues of $43.6M. AnGes's net income of -$8.2M is lower than Nxera Pharma's net income of -$5M. Notably, AnGes's price-to-earnings ratio is -- while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnGes is 22.97x versus 3.51x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of -737.34% compared to AnGes's net margin of -9.79%. AnGes's return on equity of -33.92% beat Takeda Pharmaceutical's return on equity of 1.49%.

AnGes has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $17.15 which suggests that it could grow by 13.72%. Given that Takeda Pharmaceutical has higher upside potential than AnGes, analysts believe Takeda Pharmaceutical is more attractive than AnGes.

AnGes has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.227, suggesting its less volatile than the S&P 500 by 77.347%.

AnGes has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Takeda Pharmaceutical offers a yield of 4.07% to investors and pays a quarterly dividend of $0.33 per share. AnGes pays -- of its earnings as a dividend. Takeda Pharmaceutical pays out 280.28% of its earnings as a dividend.

AnGes quarterly revenues are $1.1M, which are smaller than Takeda Pharmaceutical quarterly revenues of $6.9B. AnGes's net income of -$8.2M is higher than Takeda Pharmaceutical's net income of -$676.5M. Notably, AnGes's price-to-earnings ratio is -- while Takeda Pharmaceutical's PE ratio is 69.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnGes is 22.97x versus 1.63x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.